368 related articles for article (PubMed ID: 25833669)
1. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
3. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
5. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
Durand JP; Deplanque G; Montheil V; Gornet JM; Scotte F; Mir O; Cessot A; Coriat R; Raymond E; Mitry E; Herait P; Yataghene Y; Goldwasser F
Ann Oncol; 2012 Jan; 23(1):200-205. PubMed ID: 21427067
[TBL] [Abstract][Full Text] [Related]
7. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
[TBL] [Abstract][Full Text] [Related]
10. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
[TBL] [Abstract][Full Text] [Related]
12. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
[TBL] [Abstract][Full Text] [Related]
13. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
[TBL] [Abstract][Full Text] [Related]
14. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
[TBL] [Abstract][Full Text] [Related]
16. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
[TBL] [Abstract][Full Text] [Related]
17. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.
Zedan AH; Hansen TF; Fex Svenningsen A; Vilholm OJ
Clin Colorectal Cancer; 2014 Jun; 13(2):73-80. PubMed ID: 24365057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
